AI echo through the Viz.ai platform
Us2.ai is the FDA-cleared echocardiography AI algorithm in the Alnylam and Viz.ai ATTR-CM care pathway, combining automated echo analysis with EHR connectivity for routine clinical workflows.
The marketplace pathway for AI echo
For health systems already standardized on Viz.ai's cardiology AI platform, Us2.ai is available directly through the existing Viz.ai contract. Procurement, security review, and IT onboarding leverage the relationship already in place, which is why some sites have onboarded in as little as 6 to 9 weeks compared with the 6 to 9 months a typical direct procurement takes (NorthShore at Endeavor Health, as discussed in the ACC.25 Cardiac Wire Show interview).
Beyond marketplace distribution, Viz.ai and Us2.ai work together on disease-specific care pathways: structured clinical workflows that combine echo AI with EHR connectivity to identify candidate patients earlier in the course of disease.
The Alnylam & Viz.ai ATTR-CM care pathway
Us2.ai has been selected as the echocardiography AI algorithm powering Alnylam and Viz.ai's strategic collaboration to build an AI-enabled ATTR-CM care pathway, designed to help clinicians identify patients earlier in the course of disease and guide appropriate diagnostic evaluation and referral.
The pathway combines Us2.ai's FDA-cleared echocardiography AI with electronic health record connectivity and integration into routine clinical practice. ATTR-CM is a progressive and life-threatening cause of heart failure that remains significantly underdiagnosed, with an estimated 80% of patients worldwide yet to receive a diagnosis. Earlier identification is critical to enabling access to treatment.
The AWARE study
At the centre of the collaboration is the AWARE study: one of the first prospective, multi-system implementation studies evaluating how AI-enabled echocardiographic screening can be embedded into everyday clinical workflows. The study measures impact on diagnostic timelines, care coordination, and clinical decision-making in ATTR-CM. The initiative will launch at five pilot US health systems in 2026, with the goal of generating real-world evidence to support broader adoption across the Viz.ai network.
Single contract, faster onboarding
Sites already running on Viz.ai do not need a separate procurement track for Us2.ai. The software is accessed through the Viz.ai platform under the existing contract, and the security review and IT validation already completed for the marketplace carry forward. Results are surfaced inside the workflow that reading cardiologists already use.
For health systems considering AI echo, the marketplace pathway is the fastest route to a working deployment.
Us2.ai on the ACC.25 Cardiac Wire Show
How AI echo plugs into the Viz.ai marketplace, including the 6–9 week onboarding timeline at NorthShore at Endeavor Health.
Cleared indications
Us2.ai is FDA 510(k) cleared (K233676) and approved or registered in 28+ regulatory markets worldwide. Cleared clinical indications can differ between markets, and indications available through the Viz.ai marketplace depend on the health system's region. For confirmation of which Us2.ai capabilities are cleared in a specific country, see Regulatory Status or contact us.
Continue Exploring
Deploy Us2.ai Through Viz.ai
Already running Viz.ai? Talk to our team about turning on Us2.ai through your existing marketplace contract.
Book a Demo